人类肝细胞系5:肝免疫生物学的体外模型
Smeeta Shrestha1, Ming Yue Yeong1, Xin Yi Cheng1
1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 636921, Singapore.
Molecular biology reports
|February 3, 2026
概括
人类肝细胞5线 (HHL-5) 细胞为肝病研究提供了一个有前途的非癌性体外模型. 与肝细胞癌 (HCC) 细胞相比,这些细胞表现出不同的遗传和代谢特征,支持它们在研究肝脏健康和疾病中的使用.
科学领域:
- 肝病学和体外建模 在体外建模.
- 细胞生物学和基因组学
- 生物化学和代谢学
背景情况:
- 肝细胞癌 (HCC) 是一个重大的全球健康挑战.
- 缺乏生理学上相关的体外模型阻碍了对早期宿主病毒相互作用和肝病中的免疫反应的理解.
- 人类肝细胞系5 (HHL-5) 是一种不朽化的肝细胞细胞系,具有保留的肝脏特异性功能.
研究的目的:
- 描述HHL-5细胞的表型,遗传和代谢特征.
- 为了评估HHL-5细胞作为非癌性肝脏模型.
- 为了比较HHL-5细胞与HCC细胞系HepG2.2.的细胞系.
主要方法:
- 形态和表型评估的评估.
- 为了基因组分析,进行全外因组测序.
- 核磁共振光谱学用于代谢学分析.
- 西方涂抹用于蛋白质表达分析.
主要成果:
- HHL-5细胞表现出较小的细胞/核区域和比HepG2细胞增殖速度较慢.
- 基因组分析显示,HHL-5细胞中的免疫相关途径丰富与HepG2细胞中的DNA复制途径相比.
- 代谢分析显示了HHL-5细胞的氧化特征,与HepG2细胞的糖性表型形成鲜明对比.
- 在HHL-5细胞中,瘤原和应激反应标志物的表达减少.
结论:
- HHL-5细胞代表了一个强大的非癌症体外模型.
- 该模型适用于调查肝脏疾病和病毒感染.
- HHL-5细胞可以帮助研究肝癌发生的早期事件.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
280
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System
6.0K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
245
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
245
Hepatic Drug Excretion: Influencing Factors
589
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
589
Hepatic Drug Clearance: Role of Transporters
310
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
299
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
299


